Cargando…
Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn’s disease: results from a multicentre cohort study
BACKGROUND: Treatment with antitumor necrosis factor alpha (anti-TNF-α) is safe and effective as first-line therapy; however, its efficacy is limited due to primary nonresponse (PNR) and secondary loss of response (LOR), resulting in treatment discontinuation in approximately 40%–50% of cases. Vedol...
Autores principales: | Bacsur, Péter, Matuz, Mária, Resál, Tamás, Miheller, Pál, Szamosi, Tamás, Schäfer, Eszter, Sarlós, Patrícia, Iliás, Ákos, Szántó, Kata, Rutka, Mariann, Bálint, Anita, Milassin, Ágnes, Fábián, Anna, Bor, Renáta, Szepes, Zoltán, Molnár, Tamás, Farkas, Klaudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806440/ https://www.ncbi.nlm.nih.gov/pubmed/36600684 http://dx.doi.org/10.1177/17562848221144349 |
Ejemplares similares
-
Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination
por: Resál, Tamás, et al.
Publicado: (2023) -
Conception and reality: Outcome of SARS-CoV-2 infection and vaccination among Hungarian IBD patients on biologic treatments
por: Resál, Tamás, et al.
Publicado: (2022) -
Still the Joker in the Pack: When to Take Out Cyclosporine in the Game?
por: Resál, Tamás, et al.
Publicado: (2021) -
Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls
por: Bacsur, Péter, et al.
Publicado: (2023) -
The complex relationship between viruses and inflammatory bowel disease – review and practical advices for the daily clinical decision-making during the SARS-CoV-2 pandemic
por: Farkas, Klaudia, et al.
Publicado: (2021)